Clinical Trial Update: PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating a PD-1 antibody as adjuvant therapy for gastric cancer patients with MSI-H following D2 radical surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Fudan University | Conditions: MSI-H, PD-1 Immunotherapy | Phase 2 | Status: UNKNOWN